A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and

Protocol No

MEI-ME-522-001

Principal Investigator

Sameem Abedin

Phase

I

Summary

Voruciclib blocks a molecule called cyclin-dependent Kinase (CDK), which then decreases the amount of another molecule, called myeloid cell leukemia protein 1 (Mcl-1). Mcl-1 shows up in large amounts in B cell type cancers. It is thought that blocking Mcl-1may stop the growth of B cell type cancers or enable other drugs to work more effectively.

Description

This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

Sub Category

Early Phase/Multiple Disease Site Cancers, Hematologic/Blood Related Cancers

ClinicalTrials.gov

go to website

A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia